



QUEST DIAGNOSTICS INCORPORATED
CLIENT SERVICE 800.553.5445

SPECIMEN INFORMATION

SPECIMEN: 31234567
REQUISITION: 20000012

COLLECTED: 08/26/2003 00:00
RECEIVED: 08/28/2003 08:50
REPORTED: 09/03/2003 19:42

PATIENT INFORMATION
SAMPLE PATIENT C

DOB: 01/01/53 AGE: 50
GENDER: M FASTING:
SS: NOT GIVEN
PHONE:

REPORT STATUS FINAL

ORDERING PHYSICIAN

CLIENT INFORMATION
5434 23
QUEST DIAGNOSTICS INCORPORATED

ERIE, PA

HIV-1 Genotype

Antiretroviral Drugs ¹	Predicted Resistance ²	Mutations/Results Detected on 09/03/2003
HIV-1 Subtype ³ : B		
NRTIs RT codons 1-400		
ZDV (zidovudine or Retrovir®)		
ABC (abacavir or Ziagen®)		K65R, L74V
ddl (didanosine or Videx®)		K65R, L74V
3TC (lamivudine or Epivir®)		
FTC (Emtricitabine or Emtriva™)		
d4T (stavudine or Zerit®)		
ddC (zalcitabine or Hivid®)		K65R, L74V
TDF (tenofovir or Viread®)		K65R
NNRTIs		
DLV (delavirdine or Rescriptor®)		
EFV (efavirenz or Sustiva®/Stocrin®)		G190Q
NVP (nevirapine or Viramune®)		G190Q
PIs PR codons 1-99		
APV (amprenavir or Agenerase®)		
IDV (indinavir or Crixivan®)		
NFV (nelfinavir or Viracept®)		
RTV (ritonavir or Norvir®)		
SQV (saquinavir or Invirase®/Fortovase®)		
LPV (lopinavir or Kaletra®)		
ATV (atazanavir or Reyataz™)		

= Resistance Predicted = No Predicted Resistance = Probable or Emerging Resistance = No Result Available

Other mutations detected (current specimen only)
RT gene mutations : NOT DETECTED
PR gene mutations : L63P, I64L



QUEST DIAGNOSTICS INCORPORATED

PATIENT INFORMATION
SAMPLE, PATIENT C

REPORT STATUS FINAL

DOB: 01/01/53 AGE: 50 ORDERING PHYSICIAN
GENDER: M FASTING:

REPORTED: 09/03/2003 19:42

¹ All Trademarks are the property of their respective owners.

² Resistance predictions for current specimen interpreted according to The Quest-Stanford August 2003 Interpretation Algorithm; prior data is based on the algorithm in use at the time of the original report.

³ Subtype determined by sequence analysis of the viral cDNA generated for this assay.

This test is performed pursuant to a license agreement with Roche Molecular Systems, Inc.

This test was developed and its performance characteristics determined by Quest Diagnostics Nichols Institute. It has not been cleared or approved by the U.S. Food and Drug Administration.

The phrases "resistance predicted" and "probable or emerging resistance" refer to the application of the interpretive rules. The FDA has not reviewed all of the interpretive rules used by the laboratory to predict drug resistance. The FDA may not currently recognize some of the HIV gene mutations reported as predictive of drug resistance, but the laboratory considers these mutations to be associated with resistance to anti-viral drugs based on current clinical or scientific studies. The test has been validated pursuant to CLIA regulations and is not considered investigational or for research use only. Treatment decisions should be made in consideration of all relevant clinical and laboratory findings and the prescribing information for the drugs.

Peter N.R. Heseltine, M.D., F.A.C.P.
Medical Director, Infectious Diseases
Quest Diagnostics Nichols Institute

PERFORMING LABORATORY INFORMATION:

Quest Diagnostics Nichols Institute, 33608 Ortega Hwy, San Juan Capistrano, CA 92690
Laboratory Director: R.E. Reitz MD, CLIA: 05D0643352